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Abstract
Background: We have previously shown that supernatant from Candida albicans (CA) culture
contains a Secretory Interleukin (IL)-12 Inhibitory Factor (CA-SIIF), which inhibits IL-12 production
by human monocytes. However, the effect of CA-SIIF on secretion of other cytokines by
monocytes is unknown, and detailed characterization of this factor has not been performed.
Results: In this study, we demonstrate that the IL-12 inhibitory activity of CA-SIIF was serum-
independent, based on the reduction of IL-12 levels in monocytes stimulated under serum-
independent conditions. The minimal inhibitory dose of CA-SIIF was found to be 200 μg/ml.
Investigation of CA-SIIF's effect on macrophages IL-12 production in vitro and in vivo also showed
that CA-SIIF inhibited IL-12 production by murine macrophages both in vitro (from 571 ± 24 pg/ml
to 387 ± 87 pg/ml; P = 0.05) and in vivo (from 262 ± 6 pg/ml to 144 ± 30 pg/ml; P < 0.05). In addition
to IL-12, cytokine array analysis revealed that CA-SIIF induced differential production of other
cytokines also. In this regard, reduction in levels were observed for IL-8, IL-10, IL-13, monocyte
chemoattractant protein (MCP)-1, MCP-2, macrophage inflammatory protein (MIP)-1, RANTES,
etc. In contrast, levels of other chemokines e.g. MCP-4, MIF and MIP-3α (P < 0.05) were increased.
We also found that CA-SIIF suppressed the maturation of human monocytes to dendritic cells
(CD1a expression = 13 ± 3% vs 36 ± 2% of the control; P < 0.01). Next, to identify the biochemical
nature of CA-SIIF, we separated this factor into a Concanavalin A (ConA)-binding glycoprotein
fraction (CA-SIIF-GP) and a non-ConA-binding protein fraction (CA-SIIF-NGP) using ConA affinity
chromatography. Both fractions were then tested for this inhibitory effect on human monocyte IL-
12 production. CA-SIIF-GP produced a higher inhibitory effect on IL-12 production compared to
CA-SIIF-NGP and CA-SIIF crude (P < 0.01), proving that CA-SIIF is a glycoprotein in nature.
Conclusion:  CA-SIIF is a glycoprotein which exhibits serum-independent inhibition of IL-12
production from monocytes in vitro and in vivo, and also modulates differentiation of monocytes into
dendritic cells. These results suggest important role for CA-SIIF in interactions of C. albicans with
the host immune system.
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Background
Infections due to the human pathogenic fungus Candida
albicans are a major cause of morbidity and mortality in
immunocompromised patients [1] and one of the most
common causes of nosocomial bloodstream infections
[2]. Host response to Candida infection is a complex inter-
play between innate and adaptive immunity, and usually
provides a sufficient defense against microbes in healthy
individuals but not in immunocompromised ones. The
first line of defense against Candida  infections are
immune cells involved in the innate immune response,
including monocytes, which can differentiate into macro-
phages [3] or dendritic cells [4] under various conditions.
The defense mechanisms activated by these immune cells
involve stimulation of pro-inflammatory cytokines like
interleukin-12 (IL-12) and/or inhibition of anti-inflam-
matory cytokines (e.g., IL-10) by the host monocytes/
macrophages. Among those cytokines, IL-12 plays an
important role in differentiating T cells and activating
Natural Killer (NK) cells, both of which produce high lev-
els of IFN-γ, leading to protective cell-mediated immunity
against Candida infection [5].
A common mechanism by which microbial pathogens
overcome host immune response is by suppressing pro-
duction of pro-inflammatory cytokines like IL-12 [6,7].
Previously, we showed that a Secretory IL-12 Inhibitory
Factor produced by C. albicans (CA-SIIF) inhibits IL-12
production by human monocytes [8]. We hypothesized
that CA-SIIF induced differential production of other
cytokines, and that CA-SIIF is a glycoprotein. To test this
hypothesis, in this study, we determined the effect of CA-
SIIF on: (a) profile of cytokines/chemokines produced by
monocytes exposed to this factor, (b) differentiation of
monocytes to dendritic cells, and (c) IL-12 production by
murine macrophages in vitro and in vivo. Furthermore, we
also performed concanavalin A (ConA) affinity chroma-
tography to isolate the glycoprotein fraction of CA-SIIF
and determined whether the IL-12 inhibitory activity is
mediated by this fraction. We found that, in addition to its
effect on IL-12 production, in the presence of CA-SIIF,
stimulated monocytes produce different levels of GRO
(Growth Related Oncogene), IL-8, IL-10, IL-13, MCP
(Monocyte Chemoattractant Protein)-1, MCP-2, MIP
(Macrophage Inflammatory Protein)-1Δ, RANTES (Regu-
lated upon activation, normal T-cell expressed, and pre-
sumably secreted), Leptin, Eotaxin-2, LIF (Leukemia
Inhibitory Factor), TIMP (Tissue inhibitor of metallopro-
teinases)-2, MCP-4, MIF (Macrophage Migration Inhibi-
tory Factor) and MIP-3α. Additionally, CA-SIIF also
inhibited differentiation of monocytes into dendritic
cells. CA-SIIF also inhibited production of IL-12 by
murine macrophages, both in vitro and in vivo. The IL-12
inhibitory activity of CA-SIIF was localized to the ConA-
based affinity purified glycoprotein fraction, suggesting
that a glycoprotein moiety mediates the inhibitory activity
of CA-SIIF. The present studies show that CA-SIIF is a glyc-
oprotein, and demonstrated that it can induce differential
production of several cytokines in addition to IL-12, and
that its mechanism of action may be mediated by inhibi-
tion of monocyte differentiation.
Methods
Fungal organisms and culture conditions
C. albicans (strain SC5314) was used in this study to
obtain CA-SIIF. A non-pathogenic yeast, Saccharomyces
cerevisiae  (strain MRL138), was used as a comparator.
Cells were grown in Yeast Nitrogen Base (YNB) (BD Bio-
sciences, Sparks, MD) for 18 h, and used as described
below for collection of CA-SIIF. Frozen stocks were main-
tained for these cultures at -80°C.
Collection of CA-SIIF
Yeast strains grown in YNB were subcultured (3 × 105
cells/ml) in RPMI 1640 medium (Mediatech, Herndon,
VA) in a shaking incubator at 37°C in 4 L volume flasks
for 20 hours. The supernatants from the above culture (or
RPMI medium as controls) were collected and transferred
to Centricon filters with a molecular weight cut-off
(MWCO) of 30 kDa (Millipore, Bedford, MA). Protein
concentrations were measured using a BCA Protein Assay
Kit (Pierce, Rockford, IL). CA-SIIF was filtered through a
0.22 μm filter unit (Millipore, Bedford, MA), aliquoted,
concentrated and stored at -80°C until use [8].
Isolation of human monocytes
Monocytes were obtained from fresh human peripheral
blood of healthy adult volunteers as described previously
[9]. Volunteers participated in this study with informed
consent after approval of the protocol by the Institutional
Review Board (IRB) of Case Western Reserve University
(CWRU) and University Hospitals of Cleveland (UHC).
Briefly, 240 ml heparinized blood was centrifuged over a
Ficoll gradient-1077 (Sigma-Aldrich, St. Louis, MO), and
adherent cells from the buffy coat were harvested and iso-
lated by negative selection using an antibody cocktail
(StemCell Technologies, Vancouver, Canada). The cell
mixture was then passed through a Magnetic Cell Separa-
tion (MACS) column against a MACS magnet (Miltenyi
Biotec, Auburnm, CA) to obtain the purified monocytes.
The purity of the monocytes was determined by flow
cytometry using CD14 positive staining and ranged
between 85%–95%.
Co-culture of monocytes and yeast supernatants
Immediately after purification, 1 × 106 monocytes in 1 ml
complete media (RPMI-1640 with 10% FBS and 1% Pen-
icillin/Streptomycin) were incubated with 50 μl CA super-
natants (50 μg, 100 μg, 200 μg and/or 300 μg, dependingBMC Microbiology 2008, 8:31 http://www.biomedcentral.com/1471-2180/8/31
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on each experiment) and primed with 5 ng/ml IFN-γ at
37°C with 5% CO2 for 16 hours, followed by another 24
hours of 50 ng/ml LPS stimulation [10]. Supernatants of
cell culture were collected and cytokine levels were meas-
ured as described below.
In vitro assay to evaluate inhibition of IL-12 production by 
murine macrophages
For in vitro studies, peritoneal macrophages were extracted
from female C57BL/6 mice 6–8 weeks of age elicited by 1
ml of 3% thioglycollate (TG), and then 2 × 106 cells in 1
ml complete media were incubated with 500 pg/ml IFN-γ
and 50 ng/ml LPS, in the presence 1 mg CA-SIIF or media
control. Finally, IL-12 levels were measured by ELISA as
described below. Experiments complied with Institutional
Animal Care and Use Committee (IACUC) guidelines of
CWRU.
In vivo assay to evaluate inhibition of IL-12 productions in 
murine macrophages
IL-12 production in vivo was optimized using female
C57BL/6 mice of 6–8 weeks age as above pretreated for 5
days with TG peritoneally (ip) and combining a priming
ip injection with 100 ng LPS with an iv injection of 1 μg
LPS 1 h later. 1 mg CA-SIIF or media control was injected
prior to LPS, and six hours later, serum was collected
(please see schematic, Figure 1). Serum IL-12 levels were
then measured by ELISA as described below. Experiments
complied with IACUC guidelines of CWRU.
Cytotoxicity of CA-SIIF and human cell viability
To exclude the possibility that CA-SIIF was potentially
toxic to mice, up to 1 mg of CA-SIIF was injected intrave-
nously into both BALB/c and C57BL/6 mice (5 per group)
and those mice were monitored daily over a 2-week
period. In vitro induction of Red Blood Cell (RBC) lysis at
different CA-SIIF protein concentrations (100–1200 μg)
was also determined, with amphotericin B (AmB, with
known toxicity against RBCs) serving as a positive control,
while fluconazole (FLU, an antifungal with very safe tox-
icity profile) as negative control. Human cell viability was
also confirmed by trypan blue staining indicating over
75% viability in each experiment.
Quantitation of IL-12p70
The levels of IL-12p70 were determined by Enzyme-
Linked Immunosorbent Assay (ELISA) using a Human IL-
12 (p70) kit (BD Biosciences, San Diego, CA). Quantities
of IL-12 p70 were expressed as pg/ml. The sensitivity of
the ELISA was ≥ 4 pg/ml. All assays were performed in
duplicates or triplicates.
Determination of cytokine/chemokine profile
Cytokines and chemokines were examined via multiplex
spot blot array for "inflammatory cytokines" to assess the
effect of CA-SIIF on monocytes. To determine changes in
the overall cytokine/chemokine profile following CA-SIIF
exposure to monocytes, we measured the levels of
cytokine response following monocyte stimulation by
IFN-γ and LPS in the presence or absence of CA-SIIF using
the Human Cytokine Antibody Array 5 (Ray Biotech, Inc.,
Norcross, GA.) [11]. Briefly, each membrane was placed
in an eight-well tray and was blocked with blocking buffer
according to manufacturer's instructions. The membrane
was incubated with 1 ml of supernatant obtained from
stimulated monocytes treated with or without CA-SIIF,
followed by biotin-conjugated anti-cytokine antibody
treatment. Next, membranes were washed and incubated
with horseradish peroxidase (HRP)-conjugated streptavi-
din and the signals were captured using a chemilumines-
cent phosphoimager (VersaDoc, BioRad Laboratories,
CA). Cytokines spots were quantified using a densitome-
ter (BioRad VersaDoc, CA) and relative values were calcu-
lated as percentage with respect to internal positive
controls (used as 100%) on each cytokine array mem-
brane. Cytokines that differed significantly from the inter-
nal controls were considered to be cytokines of interest.
Differentiation from monocytes into dendritic cells
Monocytes (5 × 105/ml) in complete media (described
above) were incubated with GM-CSF (1000 u/ml) and IL-
4 (500 u/ml) for 5 days with or without addition of 30 μl
(500 μg) CA-SIIF. After 3 washes, the monocyte-derived
dendritic cells were first incubated with purified heat-
aggregated human IgG (2.5 g/ml, Sigma-Aldrich, St.
Louis, MO) for 20 min on ice. Cells were then directly
stained with FITC-conjugated anti-CD14 (Dakocytoma-
tion, Inc. Carpinteria, CA), PE-conjugated anti-CD1a
(Caltag Laboratories, Burlingame, CA) and their appropri-
ate isotype controls. The stained cells were analyzed by
flow cytometry by using WinList software (Verity Software
House, Topsham, ME). Positive staining cells were
expressed as a percentage after subtraction of cells in the
same gate with isotype controls.
Schematic showing steps involved in the in vivo studies with  CA-SIIF Figure 1
Schematic showing steps involved in the in vivo studies with 
CA-SIIF.
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Glycoprotein isolation by ConA affinity chromatography
To separate glycoprotein and non-glycoprotein fractions
of CA-SIIF, lectin affinity chromatography was performed
using a concanavalin A (ConA)-based Glycoprotein Isola-
tion Kit (Pierce, Rockford, IL). Briefly, unfractionated CA-
SIIF containing up to 1.5 mg of total protein was first
diluted with the Binding/Wash Buffer and applied to the
ConA resin bed. Following incubation for 10 minutes, the
resin was washed and the bound glycoproteins were
eluted. After dialysis using 10 kDa MWCO Slide-A-Lyzer
Dialysis Cassettes (Pierce, Rockford, IL), samples were fur-
ther processed by 10 kDa MWCO Centricon filter (Milli-
pore, Bedford, MA). Finally, protein concentration levels
of each fraction were measured and sample volumes were
concentrated as described above.
Statistical analysis
Results were expressed as mean ± standard error (SEM) for
N number of replicated experiments. Statistical signifi-
cance of difference between groups was determined by
two-tailed Student's t test. P value of < 0.05 was consid-
ered significant.
Results
IL-12 inhibitory activity of CA-SIIF is serum-independent, 
and induced in a dose-dependent manner
Previously, we showed that CA-SIIF is secreted by C. albi-
cans grown in the presence of fetal bovine serum (FBS),
and that this factor can inhibit IL-12 production by
monocytes activated by heat-killed C. albicans (HKCA)
cells [8]. Since it is possible that factors present in FBS
and/or heat-killed C. albicans cells may influence the
inhibitory activity of CA-SIIF, we determined whether CA-
SIIF obtained from C. albicans grown in serum-free
medium also inhibited IL-12 production by monocytes.
CA-SIIF was collected from C. albicans cultures grown for
20 h in serum-free media and added in different concen-
trations (50, 100, 200 and 300 μg/ml) to monocytes co-
cultured with IFN-γ and LPS. We found that CA-SIIF
obtained from C. albicans grown in serum-free medium
also inhibited IL-12 production by monocytes. Further-
more, this inhibition was dose-dependent, with the high-
est inhibition observed for 300 μg/ml (IL-12 level = 10 ±
7 pg/ml) and the lowest for 200 μg/ml C. albicans super-
natant (IL-12 level = 251 ± 28 pg/ml), compared to
untreated monocytes (705 ± 31 pg/ml,P < 0.01 for all
comparisons). At lower concentration (100 μg/ml), this
supernatant exhibited a trend to decrease IL-12 levels, but
the decrease was not statistically significant. As expected,
supernatants obtained from S. cerevisiae (SC) (661 ± 93
pg/ml) or RPMI-1640 media controls (662 ± 63 pg/ml)
did not induce significant inhibition of IL-12 levels (P <
0.01, Figure 2). These results demonstrated that CA-SIIF is
produced by C. albicans cells in a serum-independent, but
dose-dependent manner.
CA-SIIF inhibits IL-12 production from murine 
macrophages in vitro and in vivo
Monocytes differentiate into macrophages and are the
first line of defense against Candida infection [12]. There-
fore, we determined whether CA-SIIF affects IL-12 produc-
tion by murine macrophages. Macrophages were isolated
from the peritoneum of C57BL/6 mice following TG elic-
itation, and then exposed to CA-SIIF in combination with
IFN-γ/LPS and the levels of IL-12 were determined. We
found that macrophages co-incubated with CA-SIIF pro-
duced 32% less IL-12 than those grown in its absence (IL-
12 level = 571 ± 24 pg/ml vs. 387 ± 87 pg/ml, respectively;
P = 0.05, Figure 3A). Next, we established a murine model
to investigate the influence of CA-SIIF on IL-12 produc-
tion in vivo. In this regard, CA-SIIF toxicity assays in mice
showed no signs of toxicity after injection of up to 1 mg
CA-SIIF, over a 2 week period. RBC lysis induction tests at
various CA-SIIF concentrations (100–1200 μg) were also
negative (data not shown). IL-12 production in vivo in the
presence or absence of CA-SIIF was examined using
C57BL/6 mice pretreated for 5 days with TG peritoneally
in combination with a priming ip injection of LPS (100
ng) and another iv LPS (1 μg) injection 1 h later. Prior to
the first LPS treatment, CA-SIIF was injected ip, and six
hours later, serum was collected (Figure 1). Our data
showed that the level of IL-12 detected in the sera of mice
treated with CA-SIIF was significantly decreased from 262
± 6 pg/ml to 144 ± 30 pg/ml (P < 0.05) (Figure 3B). These
CA-SIIF inhibited induced IL-12 production by human mono- cytes in a dose dependent manner Figure 2
CA-SIIF inhibited induced IL-12 production by 
human monocytes in a dose dependent manner. 1 × 
106/ml human monocytes were primed with IFN-γ for 16 
hours and activated by LPS for 24 h with supernatants (>30 
kDa) from C. albicans or from S. cerevisiae or media control 
collected under same conditions. The supernatants were 
then measured for IL-12 p70 production. Monocytes (MN), 
monocytes activated by IFN-γ and LPS, 30 kDa MWCO 
media and supernatant from S. cerevisiae served as various 
controls. MN: monocytes without activation. Activated MN: 
monocytes activated by IFN-γ and LPS. CA-SIIF: activated 
MN cultured with supernatants from C. albicans. SC: acti-
vated MN cultured with supernatants from S. cerevisiae. n ≥ 3.
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results demonstrated that CA-SIIF can decrease IL-12 pro-
duction by murine macrophages both in vitro and in vivo.
CA-SIIF alters the balance of pro- and anti-inflammatory 
cytokines
Although CA-SIIF was shown to inhibit monocyte IL-12
production, its effect on production of other cytokines/
chemokines was unknown. Since microbial pathogens are
known to overcome host immune responses by modulat-
ing levels of pro- and anti-inflammatory cytokines, we
used membrane arrays to evaluate cytokine/chemokine
profile of monocytes exposed to CA-SIIF. We found that
in addition to decreased IL-12, CA-SIIF also inhibited pro-
duction of other cytokines/chemokines including GRO,
IL-8, IL-10, IL-13, MCP-1, MCP-2, MIP-1Δ, RANTES, Lep-
tin, Eotaxin-2, LIF and TIMP-2 by monocytes. In contrast,
other chemokines like MCP-4, MIF and MIP-3α were
increased significantly (P < 0.05, Figure 4). These studies
suggested that inhibition of pro-inflammatory cytokines/
chemokines and increase of anti-inflammatory ones (e.g.
MIF) may be one of the mechanisms by which the inhib-
itory activity of CA-SIIF is mediated. Alternatively, the bal-
ance of pro- and anti- inflammatory cytokines may be
changing dynamically following CA-SIIF treatment. For
example, IL-10, an anti-inflammatory cytokine was
decreased following CA-SIIF treatment, perhaps following
an increase in levels of IL-10 prior to our sampling point.
CA-SIIF inhibits differentiation of monocytes into dendritic 
cells
Our previous data suggested CA-SIIF IL-12 inhibition
involves the Extracellular signal-regulated Kinase (ERK)
Mitogen-Activated Protein Kinase (MAPK) signaling path-
way [8]. Since ERK and p38 MAPK signaling pathways are
known to differentially regulate the maturation of mono-
cyte-derived human dendritic cells [13], we hypothesized
that CA-SIIF inhibits differentiation of human monocytes
into dendritic cells. As shown in Figure 5, flow cytometry
analysis revealed significantly reduced expression of
CD1a (a surface marker specific for dendritic cells) in
monocytes incubated with CA-SIIF compared to control
media (13 ± 3% vs 36 ± 2%; P < 0.01). These studies dem-
onstrated that CA-SIIF inhibits differentiation of human
monocytes to dendritic cells.
Glycoproteins present in CA-SIIF mediate its IL-12 
inhibitory activity
In the previous study, we showed that CA-SIIF contains a
carbohydrate component [8]. In this study, we deter-
mined whether CA-SIIF is a glycoprotein using affinity
chromatography based on binding to ConA (a lectin that
binds specifically mannosyl/glucosyl residues) [14]. We
separated ConA-binding glycoprotein fraction (CA-SIIF-
GP) and non-ConA-binding non-glycoprotein fraction
(CA-SIIF-NGP) from CA-SIIF, and determined the effect of
these fractions on IL-12 production by activated mono-
cytes. Our results showed that activated monocytes grown
in presence of CA-SIIF-GP produced significantly less IL-
12 than those grown in its absence (IL-12 level = 446 ± 29
pg/ml vs. 705 ± 31 pg/ml, respectively, P < 0.01). In con-
trast, addition of CA-SIIF-NGP was unable to induce a
similar reduction in monocytic IL-12 levels (IL-12 level =
641 ± 22 pg/ml vs. 705 ± 31 pg/ml; P < 0.01, Figure 6A).
To further demonstrate the enhanced effect of CA-SIIF
after purification, inhibition efficiencies were calculated
based on the fold decrease of monocyte IL-12 level (per
mg protein). As can be seen in Figure 6B, CA-SIIF-GP
exhibited a significantly higher IL-12 inhibition efficiency
(fold decrease = 8.2 ± 0.9) compared to crude CA-SIIF
supernatant or CA-SIIF-NGP (fold decrease = 3.2 ± 0.2 or
2.0 ± 0.7 respectively; P < 0.01). These studies demon-
strated that partial purification of CA-SIIF based on glyco-
protein properties increased CA-SIIF activity and
suggested that this inhibitory activity of CA-SIIF is medi-
ated by its glycoprotein fraction. Preliminary SDS-PAGE
CA-SIIF inhibits macrophage IL-12 production both (A) in  vitro and (B) in vivo in a murine model Figure 3
CA-SIIF inhibits macrophage IL-12 production both 
(A) in vitro and (B) in vivo in a murine model. (A) 
murine peritoneal Macrophages (MØ) were elicited by TG 
treatment and collected from the peritoneum of C57Bl/6 
mice 5 days after elicitation. 2 × 106/ml macrophages were 
cultured in the presence or absence of LPS (50 ng) and IFN-γ 
(0.5 ng) stimulation for 16 h with or without 1 mg CA-SIIF. 
Next, IL-12 levels were measured in the supernatant by 
ELISA using antibodies specific for murine IL-12 p70. (B) LPS 
(100 ng) was administered intraperitoneally immediately fol-
lowed with or without 1 mg CA-SIIF in mice 1 h prior to 
intravenous injection of LPS (1 μg) to stimulate IL-12 produc-
tion. Serum IL-12 levels were then measured. Macrophages 
alone served as controls for base line IL-12 production.
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analysis suggested that CA-SIIF protein has a molecular
weight of around 70 kDa (data not shown). Further puri-
fication and identification of this CA-SIIF glycoprotein is
currently underway in our group.
Discussion
Previous studies have demonstrated that C.albicans influ-
ences immune response (Th1/Th2 balance) patterns dur-
ing infection [15,16]. Since IL-12 plays a central role in
linking the innate and acquired immune systems [5], sup-
pression of this cytokine could be a key to survival of any
potential pathogen. IL-12 produced by monocytes/mac-
rophages has been demonstrated to play a central role in
the production of IFN-γ by NK and T cells, acting in con-
cert with IL-18, IL-1β, TNF-α and IL-2. Moreover, IL-12
stimulates both NK and T cells to produce cytokines evok-
ing an IFN-γ response. IFN-γ production results in
increased cytotoxic activity and enhanced pathogen kill-
ing. Conversely, IL-12 suppression may lead to a predom-
inant Th2 type response to Candida  infections. Our
previous studies indicate that the factor(s) responsible for
inhibition of HKCA stimulated IL-12 associated with vir-
ulent strains of C. albicans at serum culture condition, is
released into the media as a soluble secretory IL-12 inhib-
itory factor (CA-SIIF) [8]. In this study, to exclude the pos-
sible effect of serum and HKCA on further
characterization and purification of this protein, we col-
lected CA-SIIF at serum-free condition and induced IL-12
by IFN-γ priming and LPS stimulation, and compared dif-
ferent doses with media control and another supernatant
Cytokine profiles of supernatants obtained from IFN-γ and LPS stimulated monocytes cultured in presence or absence of CA- SIIF Figure 4
Cytokine profiles of supernatants obtained from IFN-γ and LPS stimulated monocytes cultured in presence or 
absence of CA-SIIF. 1 × 106/ml human monocytes were grown in the absence or presence of CA-SIIF with IFN-γ and LPS for 
40 h, their supernatants were collected, and the cytokines present in these supernatants were measured using the preprinted 
human cytokine antibody arrays 5 (Ray Biotech, Inc.). (A) differentially expressed cytokines/chemokines with P value less than 
0.05 (n = 3). (B) representative images of cytokine array membranes. (C) cytokine map of the membrane used, showing loca-
tion of cytokines on the membrane.
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obtained from the non-pathogenic control, Saccharomyces
cerevisiae. Our results suggested CA-SIIF is serum-inde-
pendent but CA-specific, and 200 μg CA-SIIF from serum-
free conditions is enough to show a significant inhibitory
effect on IL-12 production by 1 × 106 human monocytes.
This finding was used as background for performing fur-
ther investigations on CA-SIIF with human monocytes.
Macrophages, in many cases, are localized monocytes
entering damaged tissue through blood vessel epithelium
with a series of changes in morphology and biological
functions. We speculate that since human monocytes are
suppressed in their ability to produce IL-12 following
exposure to CA-SIIF, that this same phenotype can be pre-
dicted for murine macrophages as well. Therefore, we
established a mouse model to investigate the impact of
CA-SIIF on IL-12 production by murine macrophages in
vitro and in vivo. Treatment with LPS and IFN-γ resulted in
stimulation of IL-12 production, while in vitro addition or
in vivo injection of CA-SIIF repressed IL-12 production. In
this regard, IL-12 production in TG-elicited murine
peripheral macrophages was decreased by 32% and 45%
in vitro and in vivo respectively, following CA-SIIF treat-
ment. This demonstrates the same trend as human Mono-
cytes. Human monocytes stimulated by LPS and IFN-γ
were inhibited approximately 67% by CA-SIIF, as shown
above in Figure 2. The difference in the levels of IL-12
inhibition between murine macrophages and human
monocytes might be related to the state of cell differentia-
tion (monocytes versus macrophages). Significantly, these
results showed the ability of murine-derived cells to
respond to CA-SIIF in a fashion similar to that observed
for human immune cells, demonstrating the clinical rele-
vance of our results.
CA-SIIF dramatically reduces CD1a expression on human monocyte-derived dendritic cells Figure 5
CA-SIIF dramatically reduces CD1a expression on human monocyte-derived dendritic cells. (A) Impact of CA-
SIIF on GM-CSF/IL-4 induced monocyte-derived dendritic cells. (a) CD14 expression on fresh monocytes, (b) CD1a expres-
sion on monocytes after 5 day culture with GM-CSF/IL-4 in absence of CA-SIIF, (c) CD1a expression on monocytes after 5 day 
culture with GM-CSF/IL-4 in presence of CA-SIIF. Flow histograms are representative of 3 independent experiments. (B) 
Cumulative dramatic reduction of CD1a expression on human monocytes-derived dendritic cells cultured with CA-SIIF. Cell 
density: 5 × 105/ml. n = 3.
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It also has been reported that, when treated with C. albi-
cans, peripheral blood mononuclear cells produce MCP-1,
RANTES and IL-8 [17,18], and elevations of MCP-1 level
in human alveolar macrophages are also induced [19].
Provided IL-12 is inhibited by CA-SIIF, it had been our
interest to explore whether CA-SIIF has any inhibitory
effect on other pro-inflammatory cytokines and chemok-
ines. Our data shows that addition of CA-SIIF repressed
various pro-inflammatory cytokines compared to IFN-γ/
LPS-stimulated monocytes alone. Pro-inflammatory
cytokines or chemokines such as IL-8, IL-12, MCP-2, MIP-
1Δ, RANTES and two generally implicated in allergic
responses, IL-13 and Eotaxin-2, were down-regulated by
monocytes exposure to CA-SIIF. Also, three cancer-associ-
ated proteins, GRO, LIF, TIMP-2 were also down-regu-
lated, along with Leptin, an energy intake and expenditure
regulator. It is also worth mentioning that levels of the
anti-inflammatory cytokine IL-10 were also reduced sig-
nificantly, which indicates a complex interaction of
cytokines and chemokines in response to fungal infec-
tions. Interestingly, a newly reported role for IL-17A in
host defense against C. albicans infection has also been
published [20]. These authors demonstrate that IL-17A
plays a critical role in host defense. It is possible, although
we did not examine it directly in these studies, that CA-
SIIF may also suppress other anti-Candida cytokines such
as IL-17.
In our study, levels of MCP-4, MIP-3α and especially MIF,
a chemokine that inhibits macrophage migration, were
up-regulated. Overall, large scale suppression of pro-
inflammatory cytokines or chemokines and up-regulation
of specific anti-inflammatory factor like MIF suggests C.
albicans' ability to use CA-SIIF to suppress inflammatory
effects of immune cells. Such ability may contribute to
possible refractory Candida infections in patients. How-
ever, whether some of the cytokines or chemokines' differ-
ential expression were the result of a larger scale cytokine/
chemokine cross-talk remains unknown.
Dendritic cells, which are differentiated from precursor
monocytes, express Toll-like receptors and other surface
receptors interacting with pathogens, which play an active
role in host protection against Candida infections, espe-
cially in the aspect of antigen presentation [21]. Since ERK
and p38 MAPK are involved in CA-SIIF's inhibitory effect
[8] and reciprocally regulate the differentiation of mono-
cyte-derived dendritic cells [13], we suspected that the der-
ivation from monocytes to dendritic cells might also be
inhibited by CA-SIIF. By measuring cell surface markers
specific to monocytes or derived dendritic cells through
two color immunofluorescence staining flow cytometry,
we found CA-SIIF significantly decreased CD1a expres-
sion on monocyte-derived dendritic cells induced by GM-
CSF and IL-4. This provides us an increased understanding
of other aspects of CA-SIIF inhibitory effect on mono-
cytes, in terms of preventing them from becoming more
specific and mature dendritic cells, which are responsible
for local antigen presentation and establishment of (Th1)
protective immune responses against Candida infection.
Nevertheless, a recent report discovered that, even though
subpopulations of moncoyte-derived dendritic cells
(MoDCs) are phenotypically related to CD34 positive
stem cell-derived dendritic cells (CD34DCs), MoDCs
express a specific integrin VLA-6 but CD34DCs does not.
Additionally, the adhesion and binding to components of
cutaneous extracellular matrix between the two also differ,
which suggests more investigations need to be performed
before we draw a simple conclusion of CA-SIIF's effect on
other dendritic cells subpopulations [22].
Many biologically functional proteins are glycosylated.
Recent study of C. albicans secreted proteinaceous materi-
als by proteomic analysis suggests a large portion of glyc-
osylated proteins, of which many are also similar to the
components present in cell wall/surface fractions and
Glycoprotein fraction of CA-SIIF demonstrated higher inhibi- tory effect on human monocytes IL-12 production Figure 6
Glycoprotein fraction of CA-SIIF demonstrated 
higher inhibitory effect on human monocytes IL-12 
production. CA-SIIF was passed through a ConA lectin 
affinity column. Both resulting fractions and CA-SIIF crude 
were tested for the effect on IL-12 production of 1 × 106/ml 
human monocytes. (A) glycoprotein fraction (CA-SIIF-GP) 
successfully achieved higher inhibitory effect than the non-
glycoprotein (CA-SIIF-NGP) fraction (P < 0.01). (B) Inhibi-
tion efficiency of CA-SIIF-GP fraction is significantly higher 
compared to CA-SIIF crude and CA-SIIF-NGP (P < 0.01). 
Fold decrease was calculated by decrease of the IL-12 level 
by percentage; inhibition efficiency was determined by evalu-
ating the fold decrease of IL-12 level/protein dose ratio.
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were generally not considered within the classical Candida
secretome [23]. In our previous study, we hypothesized
and performed preliminary biochemical analysis to show
that IL-12 inhibitory activity of CA-SIIF might be due to
the presence of a carbohydrate(s) [8]. Thus, in this study,
to determine whether CA-SIIF is glycoprotein in nature,
we performed one-step purification of CA-SIIF by passing
the crude CA-SIIF preparation through commercially-
made ConA lectin column. Next, we evaluated the inhib-
itory effects of fractionated CA-SIIF on monocyte IL-12
production. Our results showed that the ConA-bound
glycoprotein fraction had a higher inhibitory efficiency
(fold decrease/mg sample), compared to the non-glyco-
protein fraction and the crude CA-SIIF preparation. These
results clearly demonstrated that the inhibitory activity of
CA-SIIF is mediated by glycoprotein(s) rich in high man-
nose-type and hybrid-type oligosaccharides [14]. This
purified CA-SIIF fraction allows us to perform more
detailed biochemical and molecular analyses regarding
the mechanism of action of this factor in the future.
Several studies have reported β-glucans isolated from Can-
dida  cell walls to exhibit immunomodulatory activities
[24-26]. However, isolation of glucans from Candida cell
walls involves stringent extraction steps, including treat-
ment with NaClO and dimethylsulfoxide [26], and hot
acid and alkali treatments [25,27]. While presence of
serum also induces secretion of glucans by C. albicans
[27], our studies revealed that the IL-12 inhibitory activity
of CA-SIIF was retained even in the absence of serum. Fur-
thermore, we found that IL-12 inhibitory activity of CA-
SIIF is abrogated by proteinase treatment, indicating this
activity is retained in the protein fraction of CA-SIIF and is
not due to glucan.
It has been previously shown that, after phagocytosis of C.
albicans yeast forms, monocytes failed to differentiate to
dendritic cells and their IL-12 production was also inhib-
ited. In contrast, while phagocytosis of germ tube forms of
C. albicans leads to inhibition of IL-12, the maturation
from monocytes to dendritic cells remains unaffected
[28]. Another study showed that hyphal-form of C. albi-
cans can suppress IL-12 production even in the absence of
phagocytosis [29]. Results described in the current study,
and our previous study showed that IL-12 inhibition can
also be achieved by soluble factors secreted by C. albicans
[8]. The growth medium (RPMI-1640) used in these stud-
ies is known to induce hyphal formation and we did see
more hyphae when collecting CA-SIIF, suggesting CA-SIIF
is possibly secreted more by hyphal-form of C. albicans.
Since hyphal forms of C. albicans are generally associated
with increased virulence, it is possible that CA-SIIF could
have a larger role in disease, contributing to the patho-
genicity of this organism. However, further studies need
to be done to confirm this hypothesis. Release of C. albi-
cans proteins or molecules that regulate cytokine produc-
tion is in agreement with other studies. For example, the
C. albicans Water-Soluble Mannoprotein-β-glucan Com-
plex (CAWS), which resembles the free β-1,3-D-glucan in
patient blood, is known to modulate the growth and
cytokine production of murine macrophage cell line [30].
A recent study has also found that farnesol pretreatment
reduced both IFN-γ and IL-12, but not TNF-α and exhib-
ited IL-5 increase [15].
Taken together, our studies suggest another novel way that
C. albicans may suppress the immune response, namely by
secreting CA-SIIF, which can modulate the Th1 protective
immune responses, immune cell differentiation, and
inflammatory responses.
Conclusion
Our results show that the IL-12 inhibitory activity of C.
albicans is mediated by CA-SIIF, which is a glycoprotein,
and serum-independent. Moreover, CA-SIIF inhibits IL-12
production from monocytes in vitro and in vivo, and can
regulate the differentiation of monocytes to dendritic
cells. These results suggest that CA-SIIF may play impor-
tant roles in interactions between C. albicans and the host
immune system.
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